Pharmacodynamic biomarkers of outcomes in the phase III study of lenvatinib in 131I-refractory differentiated thyroid cancer (SELECT).

被引：0
|
作者：
Tahara, Makoto
Schlumberger, Martin
Elisei, Rossella
Habra, Mouhammed Amir
Kiyota, Naomi
Dutcus, Corina
Xu, Jianbo
Zhu, Junming
Hihara, Taro
McGrath, Shannon
Matijevic, Mark
Kadowaki, Tadashi
Funahashi, Yasuhiro
Sherman, Steven I.
机构：
[1] Natl Canc Ctr Hosp East, Dept Head & Neck Med Oncol, Kashiwa, Chiba, Japan
[2] Gustave Roussy, Dept Nucl Med & Endocrine Oncol, Villejuif, France
[3] Univ Paris 11, Villejuif, France
[4] Univ Pisa, Dept Endocrinol, Pisa, Italy
[5] Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia & Hormonal Disorders, Div Internal Med, Houston, TX 77030 USA
[6] Kobe Univ Hosp, Dept Med, Div Med Oncol Hematol, Kobe, Hyogo, Japan
[7] Grad Sch Med, Kobe, Hyogo, Japan
[8] Eisai Inc, Woodcliff Lake, NJ USA
[9] Eisai & Co Ltd, Tsukuba, Ibaraki, Japan
[10] Eisai Inc, Andover, MA USA
[11] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.6014
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6014
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Defining 131I-refractory differentiated thyroid cancer: efficacy and safety of lenvatinib by 131I-refractory criteria in the SELECT trial
    Kiyota, N.
    Robinson, B.
    Shah, M.
    Hoff, A. O.
    Taylor, M.
    Li, D.
    Dutcus, C.
    Lee, E. K.
    Kim, S. B.
    Tahara, M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S578 - S578
  • [2] Effect of age and lenvatinib treatment on overall survival for patients with 131I-refractory differentiated thyroid cancer in SELECT
    Brose, Marcia S.
    Schlumberger, Martin
    Tahara, Makoto
    Wirth, Lori J.
    Robinson, Bruce
    Elisei, Rossella
    Newbold, Kate
    Kiyota, Naomi
    Hoff, Ana O.
    Dutcus, Corina
    Song, James
    Sherman, Steven I.
    Taylor, Matthew Hiram
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT)
    Schlumberger, Martin
    Tahara, Makoto
    Wirth, Lori J.
    Robinson, Bruce
    Brose, Marcia S.
    Elisei, Rossella
    Dutcus, Corina E.
    de las Heras, Begoria
    Zhu, Junming
    Habra, Mouhammed Amir
    Newbold, Kate
    Shah, Manisha H.
    Hoff, Ana O.
    Gianoukakis, Andrew G.
    Kiyota, Naomi
    Taylor, Matthew Hiram
    Kim, Sung-Bae
    Krzyzanowska, Monika K.
    Sherman, Steven I.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (18)
  • [4] EFFICACY AND SAFETY OF LENVATINIB FOR THE TREATMENT OF PATIENTS WITH 131I-REFRACTORY DIFFERENTIATED THYROID CANCER WITH AND WITHOUT PRIOR VEGF-TARGETED THERAPY
    Newbold, Kate
    Elisei, Rosella
    Taylor, Matthew Hiram
    Krzyzanowska, Monika
    Shah, Manisha H.
    Hoff, Ana O.
    Robinson, Bruce
    Dutcus, Corina
    Song, James
    Hughes, Brett
    Habra, Mouhammed Amir
    Asia-Pacific Journal of Clinical Oncology, 2015, 11 : 173 - 173
  • [5] EFFECT OF AGE AND LENVATINIB TREATMENT ON OVERALL SURVIVAL FOR PATIENTS WITH 131I- REFRACTORY DIFFERENTIATED THYROID CANCER IN SELECT
    Brose, Marcia
    Schlumberger, Martin
    Tahara, Makoto
    Wirth, Lori
    Robinson, Bruce
    Elisei, Rossella
    Newbold, Kate
    Kiyota, Naomi
    Hoff, Ana O.
    Dutcus, Corina
    Song, James
    Hughes, Brett
    Sherman, Steven
    Taylor, Matthew Hiram
    Asia-Pacific Journal of Clinical Oncology, 2015, 11 : 173 - 173
  • [6] Efficacy and safety of lenvatinib for the treatment of patients with 131I-refractory differentiated thyroid cancer with and without prior VEGF-targeted therapy.
    Newbold, Kate
    Elisei, Rossella
    Taylor, Matthew Hiram
    Krzyzanowska, Monika K.
    Shah, Manisha H.
    Hoff, Ana O.
    Robinson, Bruce
    Dutcus, Corina
    Song, James
    Habra, Mouhammed Amir
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial
    Brose, Marcia S.
    Worden, Francis P.
    Newbold, Kate L.
    Guo, Matthew
    Hurria, Arti
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (23) : 2692 - +
  • [8] A Randomized, Phase III Study of Lenvatinib in Chinese Patients with Radioiodine-Refractory Differentiated Thyroid Cancer
    Zheng, Xiangqian
    Xu, Zhengang
    Ji, Qinghai
    Ge, Minghua
    Shi, Feng
    Qin, Jianwu
    Wang, Feng
    Chen, Guang
    Zhang, Yuan
    Huang, Rui
    Tan, Jian
    Huang, Tao
    Li, Sijin
    Lv, Zhongwei
    Lin, Yansong
    Guo, Zhuming
    Kubota, Tomoki
    Suzuki, Takuya
    Ikezawa, Hiroki
    Gao, Ming
    CLINICAL CANCER RESEARCH, 2021, 27 (20) : 5502 - 5509
  • [9] ANALYSES OF A PHASE 3, MULTICENTER, DOUBLEBLIND, PLACEBO- CONTROLLED TRIAL OF LENVATINIB (E7080) IN PATIENTS WITH 131-I-REFRACTORY DIFFERENTIATED THYROID CANCER (SELECT)
    不详
    EUROPEAN THYROID JOURNAL, 2014, 3 : 12 - 250
  • [10] Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer
    Tahara, Makoto
    Kiyota, Naomi
    Hoff, Ana O.
    Badiu, Corin
    Owonikoko, Taofeek K.
    Dutcus, Corina E.
    Suzuki, Takuya
    Ren, Min
    Wirth, Lori J.
    EUROPEAN JOURNAL OF CANCER, 2021, 147 : 51 - 57
12345